NEWAMSTERDAM PHARMA CO NV (NAMS) Stock Price, Quote, News and Overview
NASDAQ:NAMS - Nasdaq - NL00150012L7 - Common Stock - Currency: USD
NAMS Quote, Performance and Key Statistics
20.03
0 (0%)
The current stock price of NAMS is 20.03 USD. In the past month the price increased by 11.28%. In the past year, price decreased by -8.2%.
NAMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About NAMS
Company Profile
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 68 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
Company Info
NEWAMSTERDAM PHARMA CO NV
Gooimeer 2-35
Naarden NOORD-HOLLAND NL
Employees: 68
Phone: 31352062971
NEWAMSTERDAM PHARMA CO NV / NAMS FAQ
What is the stock price of NEWAMSTERDAM PHARMA CO NV today?
The current stock price of NAMS is 20.03 USD.
What is the ticker symbol for NEWAMSTERDAM PHARMA CO NV stock?
The exchange symbol of NEWAMSTERDAM PHARMA CO NV is NAMS and it is listed on the Nasdaq exchange.
On which exchange is NAMS stock listed?
NAMS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEWAMSTERDAM PHARMA CO NV stock?
17 analysts have analysed NAMS and the average price target is 45.22 USD. This implies a price increase of 125.76% is expected in the next year compared to the current price of 20.03. Check the NEWAMSTERDAM PHARMA CO NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEWAMSTERDAM PHARMA CO NV worth?
NEWAMSTERDAM PHARMA CO NV (NAMS) has a market capitalization of 2.20B USD. This makes NAMS a Mid Cap stock.
How many employees does NEWAMSTERDAM PHARMA CO NV have?
NEWAMSTERDAM PHARMA CO NV (NAMS) currently has 68 employees.
What are the support and resistance levels for NEWAMSTERDAM PHARMA CO NV (NAMS) stock?
NEWAMSTERDAM PHARMA CO NV (NAMS) has a support level at 20.02 and a resistance level at 20.04. Check the full technical report for a detailed analysis of NAMS support and resistance levels.
Should I buy NEWAMSTERDAM PHARMA CO NV (NAMS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NAMS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NAMS, evaluating the profitability, health, valuation and growth aspects
- NEWAMSTERDAM PHARMA CO NV (NAMS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEWAMSTERDAM PHARMA CO NV (NAMS) Sales and EPS estimates to see what analysts future expectations are.
- NEWAMSTERDAM PHARMA CO NV (NAMS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEWAMSTERDAM PHARMA CO NV (NAMS) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEWAMSTERDAM PHARMA CO NV (NAMS) Stock Chart to make your own analysis
- NEWAMSTERDAM PHARMA CO NV (NAMS) Latest news and press-releases to stay up to date.
Does NEWAMSTERDAM PHARMA CO NV (NAMS) stock pay dividends?
NAMS does not pay a dividend.
When does NEWAMSTERDAM PHARMA CO NV (NAMS) report earnings?
NEWAMSTERDAM PHARMA CO NV (NAMS) will report earnings on 2025-05-07, before the market open.
What is the Short Interest ratio of NEWAMSTERDAM PHARMA CO NV (NAMS) stock?
The outstanding short interest for NEWAMSTERDAM PHARMA CO NV (NAMS) is 5.42% of its float. Check the ownership tab for more information on the NAMS short interest.
NAMS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NAMS. When comparing the yearly performance of all stocks, NAMS is a bad performer in the overall market: 67.97% of all stocks are doing better.
NAMS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NAMS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to NAMS. The Buy consensus is the average rating of analysts ratings from 17 analysts.